Metabolic Syndrome and Autophagy: Focus on HMGB1 Protein

Vincenza Frisardi1*, Carmela Matrone2 and Maria Elisabeth Street3

1 Clinical and Nutritional Laboratory, Department of Geriatric and NeuroRehabilitation, Arcispedale Santa Maria Nuova (AUSL-IRCCS), Reggio Emilia, Italy, 2 Division of Pharmacology, Department of Neuroscience, School of Medicine, University of Naples Federico II, Naples, Italy, 3 Division of Paediatric Endocrinology and Diabetology, Paediatrics, Department of Mother and Child, Arcispedale Santa Maria Nuova (AUSL-IRCCS), Reggio Emilia, Italy

Metabolic syndrome (MetS) affects the population worldwide and results from several factors such as genetic background, environment and lifestyle. In recent years, an interplay among autophagy, metabolism, and metabolic disorders has become apparent. Defects in the autophagy machinery are associated with the dysfunction of many tissues/organs regulating metabolism. Metabolic hormones and nutrients regulate, in turn, the autophagy mechanism. Autophagy is a housekeeping stress-induced degradation process that ensures cellular homeostasis. High mobility group box 1 (HMGB1) is a highly conserved nuclear protein with a nuclear and extracellular role that functions as an extracellular signaling molecule under specific conditions. Several studies have shown that HMGB1 is a critical regulator of autophagy. This mini-review focuses on the involvement of HMGB1 protein in the interplay between autophagy and MetS, emphasizing its potential role as a promising biomarker candidate for the early stage of MetS or disease’s therapeutic target.

Keywords: metabolic syndrome, autophagy, HMBG1, cellular homeostasis, insulin resistance, oxidative stress

INTRODUCTION

Metabolic syndrome (MetS) increases significantly morbidity and all-cause mortality worldwide (Cornier et al., 2008; Alamdari et al., 2020; Watanabe and Kotani, 2020). MetS is linked to cognitive decline and Alzheimer’s disease (AD), and this has suggested the term “metabolic-cognitive syndrome” (Frisardi et al., 2010). Over the past few decades, the prevalence of MetS, cardiovascular disease, and dementia has risen rapidly. The increasing worldwide prevalence of childhood obesity and diabetes in the young (DeBoer, 2019; Weihe and Weihrauch-Blüher, 2019) has promoted the search for biochemical markers of MetS to identify its prodromal phase or to predict the evolutionary risk. Autophagy is a degradation process facilitating homeostasis and intracellular energy balance. Emerging discoveries showed the complex and reciprocal interplay between autophagy and metabolism (Martinez-Lopez et al., 2017; Raj et al., 2020). Obesity, fatty liver disease and diabetes, the principal components of MetS, show dysregulated hepatic autophagy (Zhang et al., 2018; Allaire et al., 2019). Vice versa, glycolysis alters the autophagy self-fueling derangements in other metabolic pathways (Kiffin et al., 2006). A ubiquitous small chromatin-linked non-histone peptide, High Mobility Group Box-1 (HMGB1), has gained attention lately as a critical promoter of autophagy processes (Huebener et al., 2014). HMGB1 levels are related to inflammation (Cal et al., 2015), insulin resistance (IR), hyperglycemia (Migazzi et al., 2021), and MetS (Jialal et al., 2014; Chen et al., 2020a). Understanding the molecular bases for these
processes is essential for developing new diagnostic biomarkers and identifying new therapeutic target and subpopulations at risk. Not all obese subjects have Mets, while lean subjects could develop MetS-linked cardiovascular complications.

**METABOLIC SYNDROME (MetS): DYSFUNCTIONAL ADIPOSITY AND IR**

Metabolic and vascular factors, especially visceral obesity and IR, characterize MetS (Cornier et al., 2008). Measuring IR is demanding, and the lack of assay standardization makes new syndrome markers necessary. Chronic pro-inflammatory and pro-thrombotic states, non-alcoholic fatty liver disease (NAFLD) (Lonardo et al., 2020), and sleep apnea (Castaneda et al., 2018) contribute to the MetS entity (Jabalie et al., 2019). MetS represents a clinical spectrum where a lag time exists between a single risk factor, the syndrome’s definition and clinical consequences. Receiving a diagnosis of MetS is already too late (Reaven, 2006) compared to the possibility of having molecular markers of disease’s evolving risk. Adipose tissue (AT) is metabolically active (Kershaw and Flier, 2004; Iozzo and Guzzardi, 2016). Chronic nutrient surplus and hyperinsulinemia increase adipocytes metabolic glucose flux and lead to cell hypertrophy. As adipocytes reach the critical size, precursor cells differentiate (Longo et al., 2019). In this context, lipogenic and antilipolytic control is impaired with reduced insulin sensitivity and ectopic fat accumulation. Therefore, the inability to buffer excess metabolic substrates from nutritional overload exposes other tissues to lipotoxicity (Cornier et al., 2011). There are functional differences between healthy (insulin sensitive) and unhealthy (IR) obesity. Inflammation can induce DNA damage, such as DNA double-strand breaks (DSBs), which increase inflammation. Obesity also modifies the immune cells (Oleśky and Glass, 2010; Trim et al., 2018). Explicitly, in the AT of obese subjects, monocytes polarize to M1 macrophages and display several cytokines (including TNF-α, IL-6, HMGB1) (Zhang et al., 2017). This molecular shift aggravates the chronic inflammatory state and IR. Furthermore, an increased formation of advanced glycation products (AGE) and their signaling via specific receptors (RAGE), including redox mechanisms, mediate vascular dysfunction and end-organ failure in MetS (Fournet et al., 2018).

**OVERVIEW ON AUTOPHAGY**

Although firstly described in 1963, only in the 1990s autophagy mechanisms were elucidated with identifying autophagy-related genes (ATG) in yeast (Takeshige et al., 1992; Klionsky, 2007; Mizushima, 2018). In eukaryotic, energy deprivation and/or intense physical activity trigger the cellular self-digestion processes to secure sufficient nutrient supply (Klionsky, 2007; Maiuri et al., 2007; Mizushima et al., 2008; Levine et al., 2011; Rubinsztein et al., 2011). Besides its role in preserving normal cellular functions, autophagy participates in several diseases (Jiang and Mizushima, 2014). Many stress conditions lead to a progressive accumulation of toxic molecular components and activate autophagic processes (Leidal et al., 2018) that rely upon three primary types: microautophagy, macroautophagy, and chaperone-mediated autophagy (CMA). Macroautophagy differs from the others because the waste of damaged organelles, unneeded cellular materials, and pathogenic agents are first sequestered and encapsulated in double-membrane vesicles (autophagosomes). Then, by trafficking from the cytoplasm to the lysosomes, autophagosomes fuse with lysosomes, and their contents can be either recycled or degraded (Mehrpour et al., 2010; Lamb et al., 2013; Figure 1). Six main steps (initiation, nucleation, elongation closure, maturation, and degradation or extrusion) characterize autophagy; each of these is highly regulated (Figure 1). Beclin 1 (BCN1) belongs to the autophagy machinery, and it plays its effects by the activation of specific (BCN1)-binding proteins, autophagic inducers and autophagic inhibitors in a cell- or tissue-dependent fashion (Cuomo et al., 2019). Autophagy induction might counteract SARS-CoV-2 infection (Carmona-Gutierrez et al., 2020). Although it is far beyond the goal of this review, the speculation of autophagy as a possible druggable target in SARS-CoV-2 is undeniably and surely deserves further investigations, also regarding the hypothesized link among obesity, IR and COVID-19 (Frisardi, 2020; Street, 2020).

**AUTOPHAGY AND MetS: THE VICIOUS CIRCLE**

Various metabolic disorders showed functional defects in autophagy (Ichimura and Komatsu, 2011; Ueno and Komatsu, 2017; Barbosa et al., 2018; Ren et al., 2018; Zhang et al., 2018). Over the last years, the use of mice models, yeast screen and genome-wide analysis has considerably amplified our knowledge about this topic (Li et al., 2016; Kuma et al., 2017). Silencing of ATG promotes obesity and triggers metabolic complications. Consistently, ATG overexpression improves the metabolic profile in aged mice (Pyo et al., 2013). Since fasting activates autophagy, dietary interventions promoting autophagy has been explored (Martinez-Lopez et al., 2017). Different metabolic phenotypes have been described in various tissues, suggesting that autophagy genes are differentially expressed and activated in a tissue- and stage-specific manner during the development. However, it is worth to note that deficits in the autophagy genes, at systemic rather than tissue-specific level, affect cell adaptation to metabolic stress more and facilitates the progression from a risk factor (ex. obesity) to full-blown diseases (Lim et al., 2014; Ren et al., 2018). Nutrient limitation and multiple stress conditions upregulate autophagy because this latter serves cytoprotective functions and, reducing cellular death, limits the following inflammatory state. Indeed, autophagy could represent a protective mechanism following myocardial infarction (Czaja, 2010). Autophagy regulates adipocyte differentiation, lipid metabolism, endothelial activity, pancreatic β-cell maturation, molecular processes related to inflammation/immune responses (Ryter et al., 2014) and storing of lipids. Whenever autophagy is inhibited, lipids accumulate, and many processes’ dysregulation
FIGURE 1 | Schematic representation of macroautophagy, chaperone-mediated autophagy (CMA), and microautophagy. (A) In macroautophagy, cargos are sequestered by phagophores, which elongate and form a double membranous structure, the autophagosome. Autophagosomes then fuse with the lysosome to form autolysosomes. (1) Nucleation consists of the formation of the phagophore. A class III of phosphoinositide 3-kinases (PI3K) complex consisting of beclin 1 (BCN1), Phosphatidylinositol 3-kinase catalytic subunit type 3 (PIK3C3), Phosphoinositide 3-kinase regulatory subunit 4 (PIK3R4), UV radiation resistance-associated gene protein (UVRAG), and Autophagy And Beclin 1 Regulator 1 (AMBRA1) is required for phagophore formation. (2) Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3) complex anchors to the membrane via a phosphoethanolamine (PE) anchor (LC3-II) and triggers the elongation. (3) The phagophore sequesters cytosolic cargo and forms a double-membranous vesicle, the autophagosome. (4) Maturation, the completed autophagosome undergoes multiple maturation steps. (5) Docking and fusion, the autophagosome is released into the lysosome/autolysosome to be degraded by lysosomal hydrolases or to become available for re-usage (6). (B) In CMA (left), substrate proteins that can be damaged by various factors, such as reactive oxygen species (ROS), bind the Lysosomal Heat shock cognate 71 kDa protein (Lys-Hsc70) chaperone through a specific amino acid sequence (the KFERQ motif) and are transported across the lysosomal membrane for degradation via interaction with lysosomal-associated membrane protein 2A (Lamp2A) proteins. (C) Microautophagy (right) involves the direct engulfment of portions of the cytoplasm into lysosomes.

occurs (Czaja, 2010). Briefly, cell-intrinsic effects (e.g., nutrient metabolism, mitochondria, and lipid droplet homeostasis), cell-extrinsic effects (e.g., the release of pro-inflammatory cytokines), and potentially lack of feedback inhibition of insulin and mTORC1 (mammalian target of rapamycin-complex 1) signaling pathways interfere with autophagy mechanisms. As in a vicious circle, defects in autophagy accelerates lifestyle-induced obesity that, in turn, inhibits autophagy in the liver, muscle and AT; worsening symptomatic features of MetS (Figure 2; Yang et al., 2010; Ruderman et al., 2013; Kaur and Debnath, 2015; Ren and Xu, 2015; Che et al., 2018; Zhang et al., 2018; Menikdiwela et al., 2020). In obesity, autophagy is suppressed via an increase in mTOR activity, which is involved in different cardiovascular pathophysiology (Wang et al., 2007; Che et al., 2018; Samidurai et al., 2018). Chronic obesity-related stress with a dysregulation of insulin/mTOR signaling (Wang et al., 2007; Sohrabi et al., 2019; Menikdiwela et al., 2020) lead to autophagy machinery disruption (Figure 2). During fasting, neuroendocrine signals [e.g., insulin and Insulin Growth Factor 1 decrease vs. glucagon, fibroblast growth factor 21 (FGF21) increase] regulate autophagy tightly. Commonly, these neurohormonal signals are altered in obesity (Levine and Kroemer, 2019). Mesenchymal stem cells from patients with diabetes and MetS show changes in oxidative stress and autophagy (Kornicka et al., 2018). Both lipogenesis and adipogenesis are redox-sensitive; healthy obesity is consistent with the lack of the redox stress signature (Jankovic et al., 2015; Bañuls et al., 2017; Böhm et al., 2020). On the contrary, constant nutritional overload and oxidative pressure may compromise autophagy machinery ability to counteract metabolic derangement. As oxidative injuries accumulate, irreversible damage appears with signaling pathways disruption. Consistently, data suggest that oxidative injury may precede adipocyte dysfunction and other metabolic disorders even in yet metabolically healthy obese subjects (Jankovic et al., 2015). Evidence support an association between mitochondrial dysfunction and MetS in prediabetic and diabetic states (Bugger and Abel, 2008; Montgomery, 2019; Böhm et al., 2020). Mitophagy (selective autophagy in mitochondria) is a vital mechanism to keep stable the metabolic homeostasis (Xu et al., 2020). Therefore, enhancement of autophagy activity might be a novel therapeutic approach against organ failure’s evolving metabolic disorders.

HMGB1: A MULTIFACETED PROTEIN

High mobility group box 1 (HMGB1) is an evolutionarily highly conserved small chromatin-linked non-histone peptide, first
HMGB1 signaling (Park et al., 2004), also activating the NF-κB proinflammatory pathway (nuclear factor kappa-light-chain-enhancer of activated B cells; IL, interleukines; TNF-α, tumor necrosis factor-alpha; p53, protein 53; p73, protein 73; RB, retinoblastoma protein; Rel/ NF-κB, member of Rel/NF-κB family; ER, estrogen receptor; C, caspases, non-canonical inflammasome; RAGE, advanced glycosylation end product-specific receptor; TLR2 and TLR4, Toll-like Receptor 2 and 4; TIM-3, T-cell immunoglobulin mucin-3; CXC4, chemokine C-X-C motif receptor 4; Mac-1, macrophage-1 antigen; CD138, syndecan-1; CD24, cluster of differentiation 24; M, macrophages; IR, Insulin Resistance; AT, Adipose Tissue. HMGB1 functions as a Damage Associated Molecular Pattern (DAMP) protein in the extracellular space. A mixture of different HMGB1 isoforms (CH = reduced form; SH2: disulfide HMGB1, SH3 oxidized form) in the extracellular space activates different pathway signaling. As the disulfide HMGB1 is responsible for autophagy activation, which counteracts the metabolic consequences of MetS. During an overload of food nutrients, there is an increase in ROS. The oxidative environment modifies the Reduced/oxidized HMGB1 ratio, increasing the dysregulation in insulin/mTOR signaling, which blocks the autophagy machinery. It follows an increased risk for the “unhealthy” obese to develop MetS complications due to an imbalance among the downstream IR pathway, chronic inflammatory pattern and inability to counteract metabolic derangements via autophagy machinery disruption. HMGB1 is an autophagic regulator that mediates stress response: in normal condition, cytosolic HMGB1 as BECN1-binding protein induces autophagy. Extracellular HMGB1 binds RAGE, which inhibits mTOR and promotes autophagy. In chronic obesity and switching from insulin-sensitive to IR state, change in oxidative environment modifies the HMGB1 activity altering its inducer role in autophagy. In the nucleus, HMGB1 interact with and enhances the activities of number of transcription factors, including p53, p73, RB, Rel/NF-κB, and ER. Once released, HMGB1 binds to various receptors to activate DAMP signaling involved in multiple cellular processes. Inflammasomes are a cytosolic multiprotein complex formation that are recruited by external pathogen and/or internal stimuli. Chronic inflammasomes lead to chronic inflammatory status increasing the risk of clinical consequences of MetS. HMGB1 triggers C (Caspase-4/caspase-5) which are components of the “non-canonical inflammasome” with cytokines release and induction of pyroptosis (a kind of proinflammatory cell death combining features of both apoptosis and necrosis).

identified in the HMG family. HMGB1 (215 amino acids) is organized in three distinct regions: Box A and Box B and the C-terminal domain. While Box A and B are essential for the HMGB1 binding to DNA and thereby regulating transcription of target genes, the C-terminal domain contains the binding sites for RAGE and Toll-like receptor (TLR) (Livesey et al., 2012; Jiang et al., 2020). Each of these receptors mediates HMGB1 signals (Park et al., 2004), also activating the NF-κB proinflammatory pathway (nuclear factor kappa-light-chain-enhancer of activated B cells) (Jiang et al., 2020; Figure 2). NF-κB was also detected in the mitochondria, where it intervenes in mitochondrial dynamics, apoptosis, respiratory control, gene expression, and disease mechanisms (Albensi, 2019), HMGB1 is involved in maintaining genomic structure and function, and it is predominantly located in the nucleus in the reduced form (Tang et al., 2010a). However, a small amount of HMGB1 is also present in the cytosol, which controls cell stress responses and inhibits apoptosis (Yang et al., 2013). During inflammation, HMGB1 promotes autophagy via binding to BCN1 and ATG5 and regulating mitochondrial morphology and function (Zhu et al., 2015; Figure 2).

HMGB1 can be released either passively from damaged cells or actively from immunologically activated immune cells under distress conditions. Extracellular HMGB1 acts as an alarmin and a Damage Associated Molecular Pattern (DAMP) protein (Raucci et al., 2019) by binding to several pathogen-associated molecular patterns (PAMPs) (Jiang et al., 2020) and activating downstream signals (Figure 2). An excessive accumulation of extracellular HMGB1 has been associated with the pathogenesis of many disorders, including diabetes (Wang et al., 2016; Zhang et al., 2020; Li and Lu, 2021). HMGB1 has several extracellular receptors (Figure 2). Actually, only RAGE and TLR4 are mainly studied and reported receptors (Andersson et al., 2018). HMGB1 serves as a redox sensor. In this regard, the three conserved redox-sensitive cysteine residues Cys23, Cys45, and Cys106 play a critical role (Li et al., 2003). Depending on the redox state, HMGB1 switches from the active to the inactive conformation. In particular, when Cys106 is oxidized, HMGB1 is inactive and likely
promotes immune tolerance with the release of proinflammatory cytokines. Moreover, Cys106 oxidation induces the HMGB1 dimerization in cells exposed to oxidative stress. It follows that HMGB1 binds to DNA with a higher affinity than monomeric HMGB1, protects DNA from damage due to hydroxyl free radicals and prevents cell death (Kwak et al., 2021).

Conversely, the reduced HMGB1 form switches its activity into the proinflammatory state (Zhang et al., 2017). Although the oxidized HMGB1 is thought to be non-inflammatory, a role in promoting the intrinsic apoptotic pathway has been reported (Tang et al., 2010b). Moreover, a mixture of oxidized/reduced HMGB1 isoforms has been described in the extracellular compartments exerting different effects on cell defense mechanisms (Xue et al., 2020).

**HMGB1, AUTOPHAGY AND MetS: A SUGGESTIVE TRIANGULATION**

Accumulating evidence supports the relationship between autophagy and HMGB1. There is a mutual regulation where one's inhibition affects the release of the other (Zhang et al., 2017), while uncontrolled autophagy increases the HMGB1 release (Tang et al., 2010b; Kim et al., 2020). HMGB1 is crucial for normal autophagy functioning (Tang et al., 2010a; Foglio et al., 2019). As a transcriptional co-factor, HMGB1 regulates the expression of heat shock protein β-1 (Tang et al., 2011; Foglio et al., 2019), which sustains dynamic intracellular trafficking during autophagy. Cytosolic HMGB1 competes with Bcl-2 for interaction with BCN1 by intramolecular disulfide bridge of HMGB1 promoting BCN1-mediated autophagosomes (Kang et al., 2010; Tang et al., 2010a; Foglio et al., 2019). HMGB1 triggers autophagy through binding to RAGE (Tang et al., 2010a). This latter is a positive regulator of autophagy and a negative regulator of apoptosis during oxidative stress, DNA damage, and hypoxia (Kang et al., 2010). In *in vitro* and *in vivo* experiments, deletion, depletion or inhibition of HMGB1 reduces autophagy (Tang et al., 2010a,b). HMGB1-mediated autophagy prevents a worse evolution of several diseases (Kang et al., 2014). In contrast, conditional knockdown of HMGB1 in the liver or heart does not affect autophagy and mitochondrial quality (Huebener et al., 2014). These conflicting results could be imputable first to the difference in cellular line; second, we can hypothesize that as a DAMP, over secreted HMGB1 could play its role in a paracrine mode by linking RAGE in the target organ. In the Huebener et al. (2014) experiment, HMGB1 was deleted in hepatocytes but not in non-parenchymal liver cells. RAGE expression was only found on ductal cells and Kupffer's cells but not on hepatocytes and this could the explanation of why in the experiment performed by Huebener et al. (2014) deleted HMGB1 in hepatocytes does not alter mitophagy, autophagy, or gene expression.

Furthermore, in basal condition, maybe HMBG1 could be dispensable for autophagy. Nevertheless, under stress conditions, if we modify the cellular micro-macro environment, for example, by aging, cumulating oxidative damage or nutrients overload, HMBG1 could be essential (Ferrara et al., 2020). In atherosclerotic lesions in human carotid, BCN1 was found to co-localize with HMGB1 and were both found in foamy macrophages suggesting an interplay between HMGB1 and autophagy in atherosclerosis (Umahara et al., 2020). Further studies are re required to investigate the HMGB1 contributes to autophagy in tissue-specific contexts and conditions.

Differently than in the inflammation (Cal et al., 2015; Yao et al., 2015; Biscetti et al., 2019) and autophagy, the role exerted by HMGB1 in MetS and its potential contribution to cardiovascular complications remains mostly unexplored despite the increasing number of evidence underlining this association (van Niekerk et al., 2019). A linear relationship has been consistently observed among HMGB1 levels and inflammation, IR, and hyperglycemia (Montanini et al., 2016; Girillo et al., 2019, 2020). In particular, a study comparing control mice to MetS mice, fed with a high-fat diet, showed increased secretion of HMGB1 in the AT of the affected mice (Jialal et al., 2014). Increased circulating HMGB1 concentrations have been described in obese children with MetS compared to healthy controls (Arrigo et al., 2013).

Further, in adipocytes, HMGB1 secretion is regulated by c-Jun (Shimizu et al., 2016), a downstream mediator of the insulin receptor. HMGB1 is implicated in the development of non-alcoholic fatty liver Disease (NAFLD) by insulin receptor downstream effectors (Arrigo et al., 2013; Wang et al., 2015; Giacobbe et al., 2016). Obese pregnant women as children show high serum HMGB1 levels (Arrigo et al., 2013; Giacobbe et al., 2016), directly associated with body mass index. Circulating HMGB1 significantly increase in obese individuals and T2D patients (Wang et al., 2015). However, a larger sample size will be necessary to support the clinical relevance of HMGB1 as a potential and viable biomarker for the early diagnosis of obesity. As secreted by the macrophages within AT (Bonaldi et al., 2003), HMGB1 may promote inflammation by binding to receptors on effector cell membranes, leading to inflammatory mediators (IL-6 and TNF-α). In turn, the release of IL-6 and TNF-α leads to increased HMGB1 release, resulting in a cascade amplification of inflammation (Zhang et al., 2019).

High mobility group box 1-gene-deficient mice show several metabolic defects and die of hypoglycemia. Obese individuals are more prone to DNA damage than normal-weight adolescents (Azzarà et al., 2016; Rohde et al., 2020) but have improved the potential to repair occurred lesions. Different repair kinetics of DSBs in obese versus lean derived lymphocytes, along with differences in HMGB1 expression level, have been reported, and specifically, cytoplasmic HMGB1 is more abundant in VAT (visceral adipose tissue) of obese compared with lean subjects (Azzarà et al., 2016). To find early biomarkers of autophagy/apoptosis unbalance concerning MetS principally, HMGB1 could represent a seducing molecule (Foglio et al., 2019). Although most evidence came from studies on cancer cell lines, speculation could be made as the cancer cells are exposed to a metabolically demanding environment (Marijt et al., 2019). Conjectures concerning a pivotal role for HMBG1 could also derive from the observed increased risk among obese subjects in morbidity and mortality related to COVID-19 (Seidu et al., 2020). Shortly, HMGB1 is (1) related to an increased risk of thrombosis; (2) HMGB1 gene polymorphisms are associated with...
hypertension; (3) HMGB1 regulates ACE II receptors which act as a counterbalance to the Angiotensin-converting enzyme (ACE), the central component of the renin-angiotensin system (Chen et al., 2020b) essential for SARS-CoV-2 infection (Chen et al., 2020b; Street, 2020; Figure 1B). In vitro studies have shown that in bronchial epithelial cells, hyperglycemia increases HMGB1 while it is lowered by insulin (Montanini et al., 2016; Seidu et al., 2020), suggesting that this protein might be a vulnerability marker besides a therapeutic target.

CONCLUSION

This mini-review focused on the hypothetical involvement of HMGB1 in the current hot topic of autophagy and MetS to prompt debate and promote further experimental studies. Chronic nutrient overload impairs the autophagy mechanism’s ability to counteract the lifestyle-induced metabolic processes, and it appears that autophagy defects play a role in determining the cardiovascular complications of MetS. HMGB1, among many other functions, also regulates autophagy and therefore represents an attractive biomarker of disease evolution and a possible therapeutic target. Obese subjects have elevated serum levels of HMGB1. We underlined the possible importance of the reducing/oxidized HMGB1 ratio for predicting the risk of disease evolution in obese healthy subjects using a conceptual “autophagy bridge.” Early diagnosis of a metabolic state that will progress to MetS complications is of crucial importance.

AUTHOR CONTRIBUTIONS

VF conceived of the presented idea and planned the manuscript. CM conceived Figure 1 and VF conceived of Figure 2. All authors shared the leading role in writing the manuscript, read and agreed to the published version of the manuscript.

REFERENCES

Alamdari, N. M., Rahimi, F. S., Afagh, S., Zarghi, A., Qaderi, S., Tarki, F. E., et al. (2020). The impact of metabolic syndrome on morbidity and mortality among intensive care unit admitted COVID-19 patients. Diabetes Metab. Syndr.: Clin. Res. Rev. 14, 1979–1986. doi: 10.1016/j.dsx.2020.10.012

Albeni, B. C. (2019). What Is Nuclear Factor kappa B (NF-kB) Doing in and to the Mitochondrion? Front. Cell Dev. Biol. 2019:00154. doi: 10.3389/fcell.2019.00154

Allaire, M., Rautou, P. E., Codogno, P., and Lotersztajn, S. (2019). Autophagy in liver diseases: time for translation? J. Hepatol. 70, 985–998. doi: 10.1016/j.jhep.2019.01.026

Andersson, U., Yang, H., and Harris, H. (2016). High-mobility group box 1 protein (HMGB1) operates as an alarmine outside as well as inside cells. Semin Immunol. 38, 40–48. doi: 10.1016/j.smim.2018.02.011

Arrigo, T., Chirico, V., Salpietro, V., Munafò, C., Ferrái, V., Gitto, E., et al. (2013). High-mobility group protein B1: a new biomarker of metabolic syndrome in obese children. Eur. J. Endocrinol. 68, 631–638. doi: 10.1530/EJE-13-0037

Azzarà, A., Pirillo, C., Giovannini, C., Federico, G., and Scarpato, R. (2016). Different repair kinetic of DSBs induced by mitomycin C in peripheral lymphocytes of obese and normal weight adolescents. Mutat Res. 789, 9–14. doi: 10.1016/j.mrfmmm.2016.05.001

Bañuls, C., Rovira-Llopis, S., Lopez-Domeńech, S., Diaz-Morales, N., Grosso, R. A., and Fader, C. M. (2018). Hallmarks of Aging: An Autophagic Perspective. Front. Endocrinol. 9:790. doi: 10.3389/fendo.2018.00790

Biscetti, F., Rando, M. M., Nardella, E., Cecchini, A. L., Pecorini, G., Landolfi, R., et al., 2020a). Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22, 5551–5560. doi: 10.1093/emboj/cdq516

Bugger, H., and Abel, E. D. (2008). Molecular mechanisms for myocardial mitochondrial dysfunction in the metabolic syndrome. Clin. Sci. 114, 195–210. doi: 10.1042/CS20070166

Cal, J., Yuan, H., Wang, Q., Yang, H., Al-Abd, Y., Hua, Z., et al. (2015). HMGB1-driven inflammation and intimal hyperplasia after arterial injury involves cell-specific actions mediated by TLR4. Arterioscler. Thromb. Vasc. Biol. 35, 2579–2593. doi: 10.1161/ATVBAHA.115.305789
Olefsky, J. M., and Glass, C. K. (2010). Macrophages, inflammation, and insulin resistance. *Ann. Rev. Physiol.* 72, 219–246. doi: 10.1146/annurev-physiol-021009-135846

Park, J. S., Svetkauskaite, D., He, Q., Kim, J. Y., Strassheim, D., Ishizaka, A., et al. (2004). Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. *J. Biol. Chem.* 279, 7370–7377. doi: 10.1074/jbc.M306973200

Pyo, J. O., Yoo, S. M., Ahn, H. H., Nah, J., Hong, S. H., Kam, T. I., et al. (2013). Overexpression of Atg5 in mice activates autophagy and extends lifespan. *Nat. Commun.* 4:2300. doi: 10.1038/ncomms3300

Raj, S., Chandela, V., Kumar, A., Kesari, K. K., Asthana, S., Ruokolainen, J., et al. (2020). Molecular mechanisms of interplay between autophagy and metabolism in cancer. *Life Sci. Volume* 259, 118–184. doi: 10.1016/j.lfs.2020.118184

Rauci, A., Di Maggio, S., Savello, F., D’Ambrosio, A., Bianchi, M. E., and Capogrossi, M. C. (2019). The Janus face of HMGB1 in heart disease: a necessary update. *Cell. Mol. Life Sci.* 76, 211–229. doi: 10.1007/s00018-018-2930-9

Reaven, G. M. (2006). The metabolic syndrome: is this diagnosis necessary? *Am. J. Clin. Nutr.* 83, 1237–1247. doi: 10.1093/ajcn/83.6.1237

Ren, J., Sowers, J. R., and Zhang, Y. (2018). Metabolic Stress, Autophagy, and Cardiovascular Aging: from Pathophysiology to Therapeutics. *Trends Endocrinol. Metab.* 29, 699–711. doi: 10.1016/j.tem.2018.08.001

Ren, S. Y., and Xu, X. (2015). Role of Autophagy in Metabolic Syndrome-Associated Heart Disease. *Biochim. Biophys. Acta* 1852, 225–231. doi: 10.1016/j.bbadis.2014.04.029

Rohde, K., Renningen, T., La Cour Poulsen, L., Keller, M., and Blüher, M. (2020). Role of the DNA repair genes H2AX and HMGB1 in human fat distribution and lipid profiles. *BMJ Open Diab. Res. Care.* 8:e000831. doi: 10.1136/bmjdrcc-2019-000831

Rubinstein, D. C., Maríño, G., and Kroemer, G. (2011). Autophagy and aging. *Cell Metab.* 13, 701–711. doi: 10.1016/j.cmet.2011.04.008

Trained Innate Immunity in Human Monocytes. *Proc. Natl. Acad. Sci. U. S. A.* 102, 7013–7018. doi: 10.1073/pnas.0501146102

Xue, J., Suarez, J. S., Minna, M. L., Li, S., Gaudino, G., Pass, H. L., et al. (2020). HMGB1 as a therapeutic target in disease. *J. Cell Physiol.* 26:30125. doi: 10.1002/jcp.30125

Yang, H., Athineos, D. J., Andersson, U., and Tracey, K. J. (2013). The many faces of HMGB1: molecular-structure-functional activity in inflammation, apoptosis, and chemotaxis. *J. Leukocyte Biol.* 93, 865–873. doi: 10.1189/jlb.1212662

Yao, Y., Guo, D., Yang, S., Lin, Y., He, L., Chen, J., et al. (2015). HMGB1 gene polymorphism is associated with hypertension in Han Chinese population. *Clin. Exp. Hypertens.* 37, 166. doi: 10.3109/10401951.2014.933963

Zheng, J., Chen, L., Wang, F., Zou, Y., Li, J., Luo, J., et al. (2020). Extracellular HMGB1 exacerbates autoimmune progression and recurrence of type 1 diabetes by impairing regulatory T cell stability. *Diabetologia* 53, 987–1001. doi: 10.1007/s00125-020-04500-x

Zhang, Y., Sowers, J. R., and Ren, J. (2018). Targeting autophagy in obesity: from pathophysiology to management. *Nat. Rev. Endocrinol.* 14, 356–376. doi: 10.1038/s41574-018-0009-1

Zhang, Y., Thery, F., Wu, N. C., Luhmann, E. K., Dussurget, O., Foecke, M., et al. (2016). The in vivo ISGylome links ISG15 to metabolic pathways and pathophysiology to management. *Nat. Rev. Endocrinol.* 12, 63–75. doi: 10.1038/nrendo.2015.139